- Respiratory disease focused Verona Pharma booked a deeper third-quarter loss after it ramped up R&D spending.

Pre-tax losses for the three months through September amounted to £12.8m, compared to losses of £3.5m on-year.

The company is developing inhaled treatment candidate, ensifentrine, which acts both as a bronchodilator and an anti-inflammatory agent in a single compound.

The treatment was currently in Phase 2b clinical development for the maintenance treatment of chronic obstructive pulmonary disease and was planned to enter Phase 3 trials for this indication in 2020.

Verona Pharma may also develop ensifentrine for the treatment of cystic fibrosis and asthma.

At 9:45am: [LON:VRP] Verona Pharma PLC share price was -1.9p at 43.6p

Story provided by